Has Adam Greenbaum, MD received payments from drug or device companies?

Yes. Drug and device makers reported $238,151 in general payments to Adam Greenbaum, MD across 559 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Adam Greenbaum, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Adam Greenbaum, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Adam Greenbaum, MD

Interventional Cardiology · Atlanta, GANPI 1396813838

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 60.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $110,947 and has fallen 78.4% since, to $23,909 in 2025. Among interventional cardiology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$238,151in general payments, 2019–2025

Across 559 payments — averaging $426.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$145K
Edwards Lifesciences$77K
Abbott$10K
W. L. Gore & Associates, Inc.$3K
Boston Scientific$2K
Ancora Heart, Inc.$991
plus $503 from 5 others

$1,523,130in research payments, 2019–2025

Across 215 payments — averaging $7084.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Edwards Lifesciences$1.3M
Abbott$113K
Medtronic$105K

What the payments were for

Consulting fees$35,76815%
Speaking & faculty fees$107,22945%
Grants$5,2282%
Travel & lodging$67,37228%
Food & beverage$22,5549%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	153	$144,809
Edwards Lifesciences	281	$76,769
Abbott	46	$10,265
W. L. Gore & Associates, Inc.	44	$3,208
Boston Scientific	24	$1,604
Ancora Heart, Inc.	4	$991
Recor Medical Inc	2	$180
Abiomed	1	$150
Shockwave Medical, Inc	2	$132
Siemens Medical Solutions USA, Inc.	1	$30
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CoreValve Evolut$98,911
Edwards SAPIEN 3 Transcatheter Heart Valve$57,122
COREVALVE EVOLUT R$27,311
MitraClip$5,415
MitraClip System$2,500
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$1,627
GORE CARDIOFORM Septal Occluder$1,475
AccuCinch$991
ROTAPRO$263
RESOLUTE ONYX$168
APOLLOTM$167
GENERAL - THERAPIES$159
Impella$150
Mitra Clip system$147
CARDIOFORM Septal Occluder$137
OPTICROSS$128
SAPIEN 3 Ultra RESILIA$119
3F$118
STINGRAY$118
Paradise Ultrasound Renal Denervation System$113

How this compares

$238,151 in reported general payments places this provider in the 95th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia →

Medicare billing

Part B allowed, 2024

$99,340

Medicare patients

161

Services billed

264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	38	$32,969
Metoprolol Succinate	13	$367
Torsemide	16	$229
ClopidogrelClopidogrel Bisulfate	16	$153

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Atlanta

William NicholsonAtlanta$1000K
David KandzariAtlanta$982K
Pradeep YadavAtlanta$656K
Wissam JaberAtlanta$222K
Katherine KunkelAtlanta$189K
James StewartAtlanta$174K
Pratik SandesaraAtlanta$165K
Chandanreddy DevireddyAtlanta$121K
Prashant KaulAtlanta$109K
Nikoloz ShekiladzeAtlanta$108K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →